BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32048549)

  • 1. Glycoconjugate vaccines: some observations on carrier and production methods.
    MacCalman TE; Phillips-Jones MK; Harding SE
    Biotechnol Genet Eng Rev; 2019 Oct; 35(2):93-125. PubMed ID: 32048549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
    Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
    Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical studies on new proteins as carrier for glycoconjugate vaccines.
    Tontini M; Romano MR; Proietti D; Balducci E; Micoli F; Balocchi C; Santini L; Masignani V; Berti F; Costantino P
    Vaccine; 2016 Jul; 34(35):4235-4242. PubMed ID: 27317455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoconjugate vaccines and immune interference: A review.
    Dagan R; Poolman J; Siegrist CA
    Vaccine; 2010 Aug; 28(34):5513-23. PubMed ID: 20600514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carrier priming effect of CRM197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM197 and diphtheria toxoid.
    Pecetta S; Tontini M; Faenzi E; Cioncada R; Proietti D; Seubert A; Nuti S; Berti F; Romano MR
    Vaccine; 2016 Apr; 34(20):2334-41. PubMed ID: 27015733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations.
    Bröker M; Berti F; Schneider J; Vojtek I
    Vaccine; 2017 Jun; 35(25):3286-3294. PubMed ID: 28487056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data.
    Heath PT
    Pediatr Infect Dis J; 1998 Sep; 17(9 Suppl):S117-22. PubMed ID: 9781743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines.
    Tontini M; Berti F; Romano MR; Proietti D; Zambonelli C; Bottomley MJ; De Gregorio E; Del Giudice G; Rappuoli R; Costantino P; ; Brogioni G; Balocchi C; Biancucci M; Malito E
    Vaccine; 2013 Oct; 31(42):4827-33. PubMed ID: 23965218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity.
    Latz E; Franko J; Golenbock DT; Schreiber JR
    J Immunol; 2004 Feb; 172(4):2431-8. PubMed ID: 14764714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectroscopic characterisation of a series of Salmonella Typhi Vi-diphtheria toxoid glycoconjugate antigens differing in polysaccharide-protein ratio.
    Jones C; An SJ; Yoon YK; Kothari S; Sahastrabuddhe S; Carbis R
    J Pharm Biomed Anal; 2020 Mar; 181():113100. PubMed ID: 31991319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
    Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR
    Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM
    Beresford NJ; Martino A; Feavers IM; Corbel MJ; Bai X; Borrow R; Bolgiano B
    Vaccine; 2017 Jun; 35(28):3598-3606. PubMed ID: 28408122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines.
    Siber GR; Anderson R; Habafy M; Gupta RK
    Vaccine; 1995 Apr; 13(6):525-31. PubMed ID: 7483772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines.
    Sun X; Stefanetti G; Berti F; Kasper DL
    Proc Natl Acad Sci U S A; 2019 Jan; 116(1):193-198. PubMed ID: 30510007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates.
    Bröker M
    Hum Vaccin Immunother; 2016 Mar; 12(3):664-7. PubMed ID: 26327602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine.
    Whang YH; Kim SK; Yoon H; Choi SK; Baik YO; Lee C; Lee I
    PLoS One; 2020; 15(12):e0243909. PubMed ID: 33301525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
    Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
    Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines.
    Falugi F; Petracca R; Mariani M; Luzzi E; Mancianti S; Carinci V; Melli ML; Finco O; Wack A; Di Tommaso A; De Magistris MT; Costantino P; Del Giudice G; Abrignani S; Rappuoli R; Grandi G
    Eur J Immunol; 2001 Dec; 31(12):3816-24. PubMed ID: 11745403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs.
    Berti F; Micoli F
    Curr Opin Immunol; 2020 Aug; 65():42-49. PubMed ID: 32361591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.